{
    "popularityCurve": {
        "data": [
            1,
            17
        ],
        "xLabels": [
            "01:37",
            "03:38"
        ],
        "label": {
            "phrase": "pharmaceutical congress on paragraph iv disputes",
            "count": 9
        }
    },
    "clusterList": [
        {
            "phrase": "pharmaceutical congress on paragraph iv disputes",
            "count": 9
        },
        {
            "phrase": "since learning of the ap article we have discovered two studies from our manufacturer",
            "count": 1
        },
        {
            "phrase": "is irrelevant because both formulations are encompassed by the claims of the 493 patent",
            "count": 1
        },
        {
            "phrase": "depending on the circumstances a justiciable article iii controversy may continue to exist between a patentee drug company and a paragraph iv anda filer in the context of the hatch-waxman act even after the patentee drug company has granted the paragraph iv anda filer a covenant not to sue",
            "count": 1
        },
        {
            "phrase": "basic premise of double patenting is that the same invention cannot be patented twice",
            "count": 1
        },
        {
            "phrase": "although there are differences between the 812 patent and the 086 patent those differences are insufficient to support the patentability of the 812 patent in light of the 086 patent",
            "count": 1
        },
        {
            "phrase": "a dual problem is presented in that the terminal disclaimer was not only filed at or near the conclusion of trial in this action but it was also filed after the expiration of the earlier 086 patent",
            "count": 1
        },
        {
            "phrase": "the federal circuit has at least suggested in dicta that for a terminal disclaimer to be effective the earlier filed patent must not have expired at the time of the filing of the disclaimer",
            "count": 1
        },
        {
            "phrase": "because neither case involved a terminal disclaimer in the context of a section 156 patent term extension",
            "count": 1
        },
        {
            "phrase": "different but the same the unique nature of prosecuting antibody therapeutics applications under the standard patent prosecution process",
            "count": 1
        }
    ]
}